Department of Intensive Care, Peking University Shenzhen Hospital, Shenzhen, China.
Brain Inj. 2021 Apr 16;35(5):547-553. doi: 10.1080/02699052.2021.1890821. Epub 2021 Feb 27.
External validation is necessary before its clinical recommendation in new setting. The aim is to externally validate Glasgow Coma Scale-pupils score (GCS-P) in neurocritical patients and to compare its performances with Glasgow Coma Scale (GCS) and its derivatives.
GCS-P at admission was calculated for individual based on the model developed by Brennan et al. Area under the receiver operating characteristic curves (AUCs), Nagelkerke's R and Brier scores were used to assess external validity of GCS-P to predict mortality in neurocritical patients and to compare predictive performance with GCS and its derivatives.
4372 neurocritical patients from intensive care units of Beth Israel Deaconess Medical Center, United States between 2001 and 2012.
GCS-P showed good discrimination (AUC 0.847 for in-hospital mortality and 0.774 for ninety-day mortality), modest calibration (Nagelkerke's R2 33.1% for in-hospital mortality and 23.3% for ninety-day mortality). Predictive performances of GCS and its derivatives was inferior to GCS-P.
GCP-P discriminated well in between death in neurocritical patients. GCP-P improved predictive performance for short-term mortality over GCS and its derivatives in neurocritical patients. It would be a simple, early and reasonable daily routine option for prognosis assessment in neurocritical setting.
在新环境下,建议临床应用前需要进行外部验证。目的是对神经危重症患者的格拉斯哥昏迷评分-瞳孔(GCS-P)进行外部验证,并与格拉斯哥昏迷评分(GCS)及其衍生评分进行比较。
根据 Brennan 等人建立的模型,计算每个患者入院时的 GCS-P。使用受试者工作特征曲线下面积(AUC)、Nagelkerke 的 R2 和 Brier 评分来评估 GCS-P 对神经危重症患者死亡率的外部有效性,并与 GCS 及其衍生评分进行预测性能比较。
来自美国贝斯以色列女执事医疗中心重症监护病房的 4372 名神经危重症患者,时间为 2001 年至 2012 年。
GCS-P 显示出良好的区分度(院内死亡率的 AUC 为 0.847,90 天死亡率的 AUC 为 0.774),适度的校准(院内死亡率的 Nagelkerke 的 R2 为 33.1%,90 天死亡率的 Nagelkerke 的 R2 为 23.3%)。GCS 及其衍生评分的预测性能均不如 GCS-P。
GCS-P 能很好地区分神经危重症患者的死亡。与 GCS 及其衍生评分相比,GCS-P 能提高神经危重症患者短期死亡率的预测性能。它将是神经危重症患者预后评估的一种简单、早期和合理的日常选择。